FIRST MANHATTAN CO. LLC. - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.

Quarter-by-quarter ownership
FIRST MANHATTAN CO. LLC. ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$12,799
+356.0%
282
+464.0%
0.00%
Q2 2023$2,807
+24.1%
500.0%0.00%
Q1 2023$2,261
+11.3%
500.0%0.00%
Q4 2022$2,032
-32.3%
500.0%0.00%
Q3 2022$3,0000.0%500.0%0.00%
Q2 2022$3,0000.0%500.0%0.00%
Q1 2022$3,000
-94.1%
50
-92.7%
0.00%
Q4 2021$51,000
-81.7%
684
-72.5%
0.00%
-100.0%
Q3 2021$278,000
+3375.0%
2,484
+4868.0%
0.00%
Q2 2021$8,000
+33.3%
500.0%0.00%
Q1 2021$6,000
-88.7%
50
-85.7%
0.00%
Q4 2020$53,000
+112.0%
350
+16.7%
0.00%
Q3 2020$25,000
+13.6%
3000.0%0.00%
Q2 2020$22,000
+83.3%
3000.0%0.00%
Q1 2020$12,000
-33.3%
3000.0%0.00%
Q4 2019$18,000
+50.0%
3000.0%0.00%
Q3 2019$12,000
-14.3%
3000.0%0.00%
Q2 2019$14,000
+40.0%
3000.0%0.00%
Q1 2019$10,000
+25.0%
3000.0%0.00%
Q4 2018$8,000
-38.5%
3000.0%0.00%
Q3 2018$13,000
-23.5%
3000.0%0.00%
Q2 2018$17,0003000.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2021
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders